 | ||
CC-1088 is a thalidomide analogue inhibitor of phosphodiesterase 4 that was being developed up to 2005 by Celgene Corp., for treating of inflammatory diseases and myelodysplastic syndromes. Apremilast (CC-10004) was found to be a preferable.
References
CC-1088 Wikipedia(Text) CC BY-SA